OBJECTIVE: Increased serum levels of alpha-1 antitrypsin (alpha1-AT) and neopterin were observed in many diseases including different types of cancer. The aim of this work is to determine alpha1-AT and neopterin serum levels in newly diagnosed untreated non-small cell lung and prostate cancer patients and to test their relation to cancer staging. METHODS: Radial Immunodiffusion and ELISA methods were used to determine alpha1-AT and neopterin serum levels, consequently. RESULTS: alpha1-AT and neopterin mean serum levels were found to be elevated in non-small-cell lung and prostate cancer patients. In non-small cell lung cancer patients alpha1-AT was 454.5+/-129.2 mg/dL (p<0.0005) and neopterin was 7.9+/-4.2 ng/mL (p<0.0005). In prostate cancer patients alpha1-AT was 462.7+/-116.9 mg/dL (p<0.0005) and neopterin was 8.1+/-3.1 ng/mL (p<0.0005). These elevated levels were significantly correlated with the stage of cancer. The mean serum level of alpha1-AT in stages I, II, III, and IV among non-small cell lung cancer patients were 305.1, 453.6, 490.3 and 616.0 mg/dL respectively, and the mean serum levels for neopterin were 4.0, 7.0, 8.1 and 14.9 ng/mL, correspondingly. The mean serum level of alpha1-AT in stages A, B, C, and D among prostate cancer patients were 342.9, 418.5, 467.8 and 593.5 mg/dL respectively and the mean serum levels for neopterin were 4.9, 6.6, 8.7 and 11.6 ng/mL, correspondingly. CONCLUSIONS: Based on the above mentioned findings alpha1-AT and neopterin serum levels should be considered in the follow up as well as in the prognosis of cancer patients.
OBJECTIVE: Increased serum levels of alpha-1 antitrypsin (alpha1-AT) and neopterin were observed in many diseases including different types of cancer. The aim of this work is to determine alpha1-AT and neopterin serum levels in newly diagnosed untreated non-small cell lung and prostate cancerpatients and to test their relation to cancer staging. METHODS: Radial Immunodiffusion and ELISA methods were used to determine alpha1-AT and neopterin serum levels, consequently. RESULTS:alpha1-AT and neopterin mean serum levels were found to be elevated in non-small-cell lung and prostate cancerpatients. In non-small cell lung cancerpatientsalpha1-AT was 454.5+/-129.2 mg/dL (p<0.0005) and neopterin was 7.9+/-4.2 ng/mL (p<0.0005). In prostate cancerpatientsalpha1-AT was 462.7+/-116.9 mg/dL (p<0.0005) and neopterin was 8.1+/-3.1 ng/mL (p<0.0005). These elevated levels were significantly correlated with the stage of cancer. The mean serum level of alpha1-AT in stages I, II, III, and IV among non-small cell lung cancerpatients were 305.1, 453.6, 490.3 and 616.0 mg/dL respectively, and the mean serum levels for neopterin were 4.0, 7.0, 8.1 and 14.9 ng/mL, correspondingly. The mean serum level of alpha1-AT in stages A, B, C, and D among prostate cancerpatients were 342.9, 418.5, 467.8 and 593.5 mg/dL respectively and the mean serum levels for neopterin were 4.9, 6.6, 8.7 and 11.6 ng/mL, correspondingly. CONCLUSIONS: Based on the above mentioned findings alpha1-AT and neopterin serum levels should be considered in the follow up as well as in the prognosis of cancerpatients.
Authors: Mya Sanda Thein; Anita Kohli; Rohit Ram; Maria Clara Ingaramo; Alka Jain; Neal S Fedarko Journal: Cancer Biomark Date: 2017-07-04 Impact factor: 4.388
Authors: Mila Ljujic; Sanja Mijatovic; Mirna Z Bulatovic; Marija Mojic; Danijela Maksimovic-Ivanic; Dragica Radojkovic; Aleksandra Topic Journal: Pathol Oncol Res Date: 2016-09-12 Impact factor: 3.201
Authors: Chae Hwa Kwon; Hye Ji Park; Jin Hwa Choi; Ja Rang Lee; Hye Kyung Kim; Hong-Jae Jo; Hyun Sung Kim; Nahmgun Oh; Geun Am Song; Do Youn Park Journal: Oncotarget Date: 2015-08-21